Aligos Therapeutics Investor Relations Material

Aligos Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the development of novel therapeutics to address unmet medical needs in viral and liver diseases. The company's development pipeline includes drug candidates for the treatment of conditions such as non-alcoholic steatohepatitis (NASH), chronic hepatitis B (CHB), and coronavirus. Aligos Therapeutics utilizes a combination of small molecule and oligonucleotide platforms to create pharmacologically optimized drug candidates aimed at improving treatment outcomes in these diseases. The company is headquartered in South San Francisco, California, and its shares are listed on the Nasdaq.